14results about "Fusions for enhanced expression stability/folding" patented technology

The present invention relates to methods and transformed host cells for the production of eriodictyol from naringenin via bioconversion.

Disclosed are fusion polypeptides that are substrates for white Kunitz's transglutaminase. The fusion polypeptides comprise one or more FKBP chaperone proteins and a target polypeptide. Each of these elements is separated from adjacent elements by a linker amino acid sequence. It has been found that it is advantageous to insert a glutamic acid-containing transglutaminase recognition motif into the linker amino acid chain. The subsequent labeling reaction catalyzed by the transglutaminase surprisingly provides a labeled fusion polypeptide with superior properties compared to chemically randomly labeled fusion polypeptides of similar design. Assays and kits for detecting a target antibody in a sample in vitro are provided.

The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens. The hyperbarically inactivated microorganisms are safer and more immunogenic than chemically inactivated microorganisms. Similarly, the solubilized proteins have superior properties compared to more heavily aggregated proteins, including reduced non-specific immune reactions.

A variant polypeptide of fructanase, a fusion protein and an enzyme composition comprising said variant polypeptide, recombinant host cell producing the variant polypeptide, method for manufacturing the variant polypeptide, a use of the variant polypeptide to degrade and modify fructan containing material, and a premix for baking comprising the variant polypeptide.

This document provides a recombinant polypeptide comprising an engineered extracellular domain of a respiratory syncytial virus (RSV) fusion (F) protein, wherein the extracellular domain comprises an engineered C-terminal α-helical region and / or amino acid substitutions, the amino acid substitutions stabilizing the F protein in its pre-fusion conformation. This disclosure also provides a two-component protein nanostructure comprising a first trimer component and a second pentamer component. This document provides a composition for use in vaccination, inducing an immune response, or treating or preventing RSV disease.

The present application relates to a protein phase separation regulation system and application thereof. The protein phase separation regulation system comprises: a target protein having a phase separation characteristic; a regulation tag connected to the target protein, the regulation tag comprising a SUMO tag; and an enzyme cutting site between the regulation tag and the target protein, the enzyme cutting site comprising a TEV enzyme cutting site. In the above protein phase separation regulation system, the design of the SUMO tag can effectively inhibit the non-specific aggregation of the phase separation element, the SUMO tag has the characteristics of a natural protein, has strong biological compatibility, reduces the toxic effect on cells, the introduction of the TEV enzyme cutting site makes the induction of phase separation have timeliness and controllability, can accurately induce phase separation at the required moment, has good flexibility, the construction and operation of the system are relatively simple, easy to implement, and can realize the response to the dynamic change in cells.

The present invention relates to proteins, adenoviruses and vaccines against infection by SARS-CoV-2 Omicron XBB subvariants, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic drugs for preventing and / or treating infections by SARS-CoV-2 Omicron XBB variants and subvariants thereof, the present invention provides proteins, adenoviruses and vaccines for preventing and / or treating infection by SARS-CoV-2 Omicron XBB subvariants, wherein these vaccines are optimized and designed based on a full-length S protein, and the receptor-binding domain (RBD) and receptor-binding domain and heptad repeat (RBD-HR) sequences in the S protein of the SARS-CoV-2 Omicron XBB subvariants, specifically, XBB.1.16, XBB.1.5, XBB.1.16.6, BA.2.86, EG.5, JN.1, XBB.2.3 and XBB.2, and are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron XBB subvariants.

Providing a protein with predictable liquid-to-liquid phase separation. [Solution] Peptide biomacromolecules exhibiting controlled phase separation based on their amino acid sequence, aromatic:aliphatic ratio, hydrophobicity, temperature, molecular weight, and concentration are described herein.

A novel class of fusion proteins is disclosed to recruit cellular innate chaperones, particularly the Hsp70-mediated system, to specifically reduce TDP-43-mediated protein aggregation and associated protein conformation disorders.

The present invention relates to: a fusion protein comprising a peptide antigen and a human thioredoxin protein linked to the N-terminus, the C-terminus or both of the peptide antigen, wherein all cysteine residues in the amino acid sequence of the human thioredoxin protein are substituted with non-cysteine residues; a nucleic acid molecule encoding the fusion protein; an expression vector comprising the nucleic acid molecule; a cell transformed with the expression vector; and a composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

Provided are compositions, kits, and methods for delivering a proteinaceous cargo, or a protein or a peptide, or a drug or a marker, to or into a cell or to an individual in need thereof. In alternative embodiments, products of manufacture as provided herein comprise: (a) a recombinant bacterial Contractile Injection System (CIS) or a Metamorphosis Associated Contractile structure (MAC) formed or configured to comprise a tube having an inner core, (b) a Metamorphosis-Inducing Factor 1 (Mif1) protein positioned in the inner core of the tube of the CIS or MAC, (c) a chaperone 605 protein non-covalently associated with the Mif1 protein positioned in the inner core of the tube of the CIS or MAC, and (d) a proteinaceous cargo, or a heterologous protein or peptide, or compound, non-covalently associated or covalently associated or linked to the Mif1.

A variant polypeptide of fructanase, a fusion protein and an enzyme composition comprising said variant polypeptide, recombinant host cell producing the variant polypeptide, method for manufacturing the variant polypeptide, a use of the variant polypeptide to degrade and modify fructan containing material, and a premix for baking comprising the variant polypeptide.

The application discloses a method for improving protein yield, which is mainly realized by screening an intron peptide variant, and the amino acid sequence of the intron peptide variant is shown in any one of SEQ ID NO. 2-4. The application also discloses a coding gene and application of the intron peptide variant and a corresponding fusion protein. The intron peptide variant has the following functions: (1) promoting the expression of a recombinant protein inclusion body, (2) being capable of significantly enhancing the renaturation effect of the recombinant protein, (3) being capable of significantly improving the purity of the recombinant protein, and (4) being capable of simultaneously reducing the proportion of a non-target protein part in the fusion protein, thereby improving the yield of the recombinant protein. The application solves the technical problems of low yield and renaturation difficulty of the recombinant protein in the existing recombinant protein production technology, and has a good commercial application prospect.

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula:wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.